TY - JOUR
T1 - Further evidence that severe scores in the aggression/anxiety-depression/ attention subscales of child behavior checklist (severe dysregulation profile) can screen for bipolar disorder symptomatology
T2 - A conditional probability analysis
AU - Uchida, Mai
AU - Faraone, Stephen V.
AU - Martelon, Marykate
AU - Kenworthy, Tara
AU - Woodworth, K. Yvonne
AU - Spencer, Thomas J.
AU - Wozniak, Janet R.
AU - Biederman, Joseph
N1 - Funding Information:
Dr. Thomas Spencer has received research support from, has been a speaker for or on a speaker bureau or has been an Advisor of on an Advisory Board of the following sources: Alcobra, Shire Laboratories, Inc, Eli Lilly & Company, Glaxo-Smith Kline, Ironshore, Janssen Pharmaceutical, McNeil Pharmaceutical, Novartis Pharmaceuticals, Cephalon, Pfizer, the National Institute of Mental Health and the Department of Defense. Dr. Spencer receives research support form Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing. Dr. Spencer has a US Patent Application pending (Provisional Number 61/233,686), through MGH corporate licensing, on a method to prevent stimulant abuse.
Funding Information:
In the past year, Dr. Faraone received consulting income and/or research support from Akili Interactive Labs, VAYA Pharma, and SynapDx and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child׳s Mental Health and Oxford University Press: Schizophrenia: The Facts.
Funding Information:
This manuscript was supported in part by grants to J. Biederman from the National Institute of Health ( NIH ) Nos. ( R01 HD36317 ; R01 MH50657 ) and the Pediatric Psychopharmacology Research Council Fund .
PY - 2014/8/20
Y1 - 2014/8/20
N2 - Background Previous work shows that children with high scores (2SD, combined score 210) on the Attention Problems, Aggressive Behavior, and Anxious-Depressed (A-A-A) subscales of the Child Behavior Checklist (CBCL) are more likely than other children to meet criteria for bipolar (BP)-I disorder. However, the utility of this profile as a screening tool has remained unclear. Methods We compared 140 patients with pediatric BP-I disorder, 83 with attention deficit hyperactivity disorder (ADHD), and 114 control subjects. We defined the CBCL-Severe Dysregulation profile as an aggregate cutoff score of 210 on the A-A-A scales. Patients were assessed with structured diagnostic interviews and functional measures. Results Patients with BP-I disorder were significantly more likely than both control subjects (Odds Ratio [OR]: 173.2; 95 Confidence Interval [CI], 21.2 to 1413.8; P<0.001) and those with ADHD (OR: 14.6; 95 CI, 6.2 to 34.3; P<0.001) to have a positive CBCL-Severe Dysregulation profile. Receiver Operating Characteristics analyses showed that the area under the curve for this profile comparing children with BP-I disorder against control subjects and those with ADHD was 99 and 85, respectively. The corresponding positive predictive values for this profile were 99 and 92 with false positive rates of<0.2 and 8 for the comparisons with control subjects and patients with ADHD, respectively. Limitations Non-clinician raters administered structured diagnostic interviews, and the sample was referred and largely Caucasian. Conclusions The CBCL-Severe Dysregulation profile can be useful as a screen for BP-I disorder in children in clinical practice.
AB - Background Previous work shows that children with high scores (2SD, combined score 210) on the Attention Problems, Aggressive Behavior, and Anxious-Depressed (A-A-A) subscales of the Child Behavior Checklist (CBCL) are more likely than other children to meet criteria for bipolar (BP)-I disorder. However, the utility of this profile as a screening tool has remained unclear. Methods We compared 140 patients with pediatric BP-I disorder, 83 with attention deficit hyperactivity disorder (ADHD), and 114 control subjects. We defined the CBCL-Severe Dysregulation profile as an aggregate cutoff score of 210 on the A-A-A scales. Patients were assessed with structured diagnostic interviews and functional measures. Results Patients with BP-I disorder were significantly more likely than both control subjects (Odds Ratio [OR]: 173.2; 95 Confidence Interval [CI], 21.2 to 1413.8; P<0.001) and those with ADHD (OR: 14.6; 95 CI, 6.2 to 34.3; P<0.001) to have a positive CBCL-Severe Dysregulation profile. Receiver Operating Characteristics analyses showed that the area under the curve for this profile comparing children with BP-I disorder against control subjects and those with ADHD was 99 and 85, respectively. The corresponding positive predictive values for this profile were 99 and 92 with false positive rates of<0.2 and 8 for the comparisons with control subjects and patients with ADHD, respectively. Limitations Non-clinician raters administered structured diagnostic interviews, and the sample was referred and largely Caucasian. Conclusions The CBCL-Severe Dysregulation profile can be useful as a screen for BP-I disorder in children in clinical practice.
KW - Bipolar disorder
KW - CBCL
KW - Mood disorders
KW - Screening instrument
KW - Severity of illness index
UR - http://www.scopus.com/inward/record.url?scp=84900416232&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2014.04.021
DO - 10.1016/j.jad.2014.04.021
M3 - Article
C2 - 24882182
AN - SCOPUS:84900416232
SN - 0165-0327
VL - 165
SP - 81
EP - 86
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -